Skip to content
10-K

Annual Report

enGene Therapeutics Inc. ENGN ENGNW

0001193125-25-328743

← back to feed
Filed
Dec 22, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Dec 18, 2025 66.98M sh
Shares Diluted FY 2025 · Oct 31, 2025 51.12M sh
Shares Diluted FY 2025 · Oct 31, 2024 37.78M sh
Capex FY 2025 · Oct 31, 2025 $1.49M
Capex FY 2025 · Oct 31, 2024 $925K
Operating Cash Flow FY 2025 · Oct 31, 2025 −$99.24M
Operating Cash Flow FY 2025 · Oct 31, 2024 −$48.28M
Cash And Equivalents FY 2025 · Oct 31, 2025 $50.15M
Cash And Equivalents FY 2025 · Oct 31, 2024 $173M
Stockholders Equity FY 2025 · Oct 31, 2025 $167.71M
Stockholders Equity FY 2025 · Oct 31, 2024 $272.61M
Stockholders Equity FY 2025 · Oct 31, 2023 $72.49M
Current Liabilities FY 2025 · Oct 31, 2025 $31.98M
Current Liabilities FY 2025 · Oct 31, 2024 $14.66M
Total Liabilities FY 2025 · Oct 31, 2025 $53.76M
Total Liabilities FY 2025 · Oct 31, 2024 $38.56M
Current Assets FY 2025 · Oct 31, 2025 $201.39M
Current Assets FY 2025 · Oct 31, 2024 $247.36M
Total Assets FY 2025 · Oct 31, 2025 $221.47M
Total Assets FY 2025 · Oct 31, 2024 $311.17M
Eps Diluted FY 2025 · Oct 31, 2025 $2.29
Eps Diluted FY 2025 · Oct 31, 2024 $1.46
Eps Basic FY 2025 · Oct 31, 2025 $2.29
Eps Basic FY 2025 · Oct 31, 2024 $1.46
Sga Expense FY 2025 · Oct 31, 2025 $28.69M
Sga Expense FY 2025 · Oct 31, 2024 $23.98M
Rd Expense FY 2025 · Oct 31, 2025 $94.48M
Rd Expense FY 2025 · Oct 31, 2024 $38.32M
Net Income FY 2025 · Oct 31, 2025 −$117.3M
Net Income FY 2025 · Oct 31, 2024 −$55.14M
Operating Income FY 2025 · Oct 31, 2025 −$123.17M
Operating Income FY 2025 · Oct 31, 2024 −$62.3M